Brown Capital Management LLC Has $404,000 Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Brown Capital Management LLC trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 79.9% during the third quarter, HoldingsChannel reports. The fund owned 9,261 shares of the company’s stock after selling 36,781 shares during the period. Brown Capital Management LLC’s holdings in Omnicell were worth $404,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System increased its holdings in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after purchasing an additional 357 shares in the last quarter. Diversified Trust Co raised its position in Omnicell by 3.3% in the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after buying an additional 494 shares during the last quarter. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Omnicell by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after acquiring an additional 600 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Omnicell by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after acquiring an additional 626 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OMCL has been the subject of several recent research reports. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Bank of America restated a “neutral” rating and issued a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upped their price objective on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Omnicell currently has a consensus rating of “Hold” and an average price target of $50.83.

Omnicell Stock Performance

OMCL opened at $41.82 on Thursday. The stock has a fifty day moving average of $44.19 and a 200-day moving average of $37.20. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The company has a market capitalization of $1.94 billion, a P/E ratio of -107.23, a P/E/G ratio of 35.67 and a beta of 0.81.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.